Bangladesh
· Delayed Price · Currency is BDT Orion Pharma Statistics
Total Valuation
Orion Pharma has a market cap or net worth of BDT 11.61 billion. The enterprise value is 35.20 billion.
| Market Cap | 11.61B |
| Enterprise Value | 35.20B |
Important Dates
The next estimated earnings date is Tuesday, November 26, 2024.
| Earnings Date | Nov 26, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Orion Pharma has 234.00 million shares outstanding.
| Shares Outstanding | 234.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 25.83% |
| Owned by Institutions (%) | 0.03% |
| Float | 159.16M |
Valuation Ratios
The trailing PE ratio is 25.48.
| PE Ratio | 25.48 |
| Forward PE | n/a |
| PS Ratio | 1.01 |
| PB Ratio | 0.53 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 29.14, with an EV/FCF ratio of -28.82.
| EV / Earnings | 77.29 |
| EV / Sales | 3.06 |
| EV / EBITDA | 29.14 |
| EV / EBIT | 50.63 |
| EV / FCF | -28.82 |
Financial Position
The company has a current ratio of 1.86, with a Debt / Equity ratio of 95.94.
| Current Ratio | 1.86 |
| Quick Ratio | 1.46 |
| Debt / Equity | 95.94 |
| Debt / EBITDA | 18.64 |
| Debt / FCF | -18.30 |
| Interest Coverage | 4.60 |
Financial Efficiency
Return on equity (ROE) is 2.01% and return on invested capital (ROIC) is 0.95%.
| Return on Equity (ROE) | 2.01% |
| Return on Assets (ROA) | 0.81% |
| Return on Capital (ROIC) | 0.95% |
| Revenue Per Employee | 4.23M |
| Profits Per Employee | 167,695 |
| Employee Count | 2,716 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 4.39 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.69% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -37.69% |
| 50-Day Moving Average | 60.35 |
| 200-Day Moving Average | 71.81 |
| Relative Strength Index (RSI) | 43.34 |
| Average Volume (20 Days) | 1,418,822 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orion Pharma had revenue of BDT 11.50 billion and earned 455.46 million in profits. Earnings per share was 1.95.
| Revenue | 11.50B |
| Gross Profit | 2.17B |
| Operating Income | 686.03M |
| Pretax Income | 563.71M |
| Net Income | 455.46M |
| EBITDA | 1.18B |
| EBIT | 686.03M |
| Earnings Per Share (EPS) | 1.95 |
Balance Sheet
The company has 250.87 million in cash and 22.34 billion in debt, giving a net cash position of -22.07 billion or -94.31 per share.
| Cash & Cash Equivalents | 250.87M |
| Total Debt | 22.34B |
| Net Cash | -22.07B |
| Net Cash Per Share | -94.31 |
| Equity (Book Value) | 23.29B |
| Book Value Per Share | 93.01 |
| Working Capital | 7.50B |
Cash Flow
In the last 12 months, operating cash flow was 1.62 billion and capital expenditures -2.84 billion, giving a free cash flow of -1.22 billion.
| Operating Cash Flow | 1.62B |
| Capital Expenditures | -2.84B |
| Free Cash Flow | -1.22B |
| FCF Per Share | -5.22 |
Margins
Gross margin is 18.85%, with operating and profit margins of 5.97% and 3.96%.
| Gross Margin | 18.85% |
| Operating Margin | 5.97% |
| Pretax Margin | 4.90% |
| Profit Margin | 3.96% |
| EBITDA Margin | 10.26% |
| EBIT Margin | 5.97% |
| FCF Margin | -10.62% |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 2.02%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 2.02% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 23.81% |
| Buyback Yield | n/a |
| Shareholder Yield | 2.02% |
| Earnings Yield | 3.92% |
| FCF Yield | -10.52% |
Stock Splits
The last stock split was on May 27, 2013. It was a forward split with a ratio of 1.2.
| Last Split Date | May 27, 2013 |
| Split Type | Forward |
| Split Ratio | 1.2 |